Literature DB >> 1748049

Ascitic fluid and serum cefotaxime and desacetyl cefotaxime levels in patients treated for bacterial peritonitis.

B A Runyon1, E A Akriviadis, F R Sattler, J Cohen.   

Abstract

Forty-one episodes of ascitic fluid infection were treated with cefotaxime 2 g intravenously every 8 hr, and ascitic fluid and serum were sampled 6, 12, 24, 48, and 96 hr after the first dose of antibiotic. Concentrations of cefotaxime and desacetyl cefotaxime were measured in ascitic fluid and serum by high-performance liquid chromatography. There was essentially 100% penetration of cefotaxime and metabolite from serum into ascitic fluid at all time points. Ascitic fluid was sterilized in 94% of episodes after the first dose of antibiotic. The ascitic fluid concentration of cefotaxime 6 hr after the first dose of antibiotic was greater than 20 times the minimal inhibitory concentration of the drug for 90% of the isolated flora. This rapid ascitic fluid penetration of cefotaxime in high concentration explains the rapid sterilization of ascitic fluid by the drug in the setting of bacterial peritonitis and obviates the need to give a loading dose or intraperitoneal injection.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1748049     DOI: 10.1007/bf01296625

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  15 in total

1.  Determination of cephalosporins and decomposition products by liquid chromatography with indirect electrochemical detection.

Authors:  H Fabre; W T Kok
Journal:  Anal Chem       Date:  1988-01-15       Impact factor: 6.986

2.  Unpredictability of clinical evaluation of renal function in cirrhosis. Prospective study.

Authors:  M A Papadakis; A I Arieff
Journal:  Am J Med       Date:  1987-05       Impact factor: 4.965

3.  Aminoglycoside nephrotoxicity in cirrhosis. Value of urinary beta 2-microglobulin to discriminate functional renal failure from acute tubular damage.

Authors:  J Cabrera; V Arroyo; A M Ballesta; A Rimola; J Gual; M Elena; J Rodes
Journal:  Gastroenterology       Date:  1982-01       Impact factor: 22.682

4.  Cefotaxime concentrations in ascites.

Authors:  L Moreau; H Durand; P Biclet
Journal:  J Antimicrob Chemother       Date:  1980-09       Impact factor: 5.790

5.  Antibiotic concentrations in ascitic fluid of patients with ascites and bacterial peritonitis.

Authors:  D N Gerding; W H Hall; E A Schierl
Journal:  Ann Intern Med       Date:  1977-06       Impact factor: 25.391

6.  Utility of an algorithm in differentiating spontaneous from secondary bacterial peritonitis.

Authors:  E A Akriviadis; B A Runyon
Journal:  Gastroenterology       Date:  1990-01       Impact factor: 22.682

Review 7.  [Concentrations of cefotaxime in human tissues and fluids. A review of published data (author's transl)].

Authors:  J Galy; O Mantel
Journal:  Nouv Presse Med       Date:  1981-02-26

8.  Culture-negative neutrocytic ascites: a variant of spontaneous bacterial peritonitis.

Authors:  B A Runyon; J C Hoefs
Journal:  Hepatology       Date:  1984 Nov-Dec       Impact factor: 17.425

9.  Altered gentamicin distribution in ascitic patients.

Authors:  M A Gill; J W Kern
Journal:  Am J Hosp Pharm       Date:  1979-12

10.  Cefotaxime is more effective than is ampicillin-tobramycin in cirrhotics with severe infections.

Authors:  J Felisart; A Rimola; V Arroyo; R M Perez-Ayuso; E Quintero; P Gines; J Rodes
Journal:  Hepatology       Date:  1985 May-Jun       Impact factor: 17.425

View more
  14 in total

Review 1.  Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness.

Authors:  Rina Mehrotra; Raffaele De Gaudio; Mark Palazzo
Journal:  Intensive Care Med       Date:  2004-11-05       Impact factor: 17.440

2.  Guidelines on the management of ascites in cirrhosis.

Authors:  K P Moore; G P Aithal
Journal:  Gut       Date:  2006-10       Impact factor: 23.059

3.  Ascitic fluid analysis for diagnosis and monitoring of spontaneous bacterial peritonitis.

Authors:  Oliviero Riggio; Stefania Angeloni
Journal:  World J Gastroenterol       Date:  2009-08-21       Impact factor: 5.742

Review 4.  Gut microbiota-related complications in cirrhosis.

Authors:  Isabel Gómez-Hurtado; José Such; Yolanda Sanz; Rubén Francés
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

5.  Ascites.

Authors:  Nelson Garcia; Arun J. Sanyal
Journal:  Curr Treat Options Gastroenterol       Date:  2001-12

6.  Spontaneous bacterial empyema in patients with liver cirrhosis in Upper Egypt: prevalence and causative organisms.

Authors:  Hoda A Makhlouf; Khairy Hammam Morsy; Nahed A Makhlouf; Eman Nasr Eldin; Mahmoud Khairy
Journal:  Hepatol Int       Date:  2012-05-04       Impact factor: 6.047

Review 7.  Cefotaxime. A reappraisal of its antibacterial activity and pharmacokinetic properties, and a review of its therapeutic efficacy when administered twice daily for the treatment of mild to moderate infections.

Authors:  R N Brogden; C M Spencer
Journal:  Drugs       Date:  1997-03       Impact factor: 9.546

Review 8.  Listeria monocytogenes peritonitis in cirrhotic patients. Value of ascitic fluid gram stain and a review of literature.

Authors:  M H Nguyen; V L Yu
Journal:  Dig Dis Sci       Date:  1994-01       Impact factor: 3.199

9.  Treatment of Ascites.

Authors:  Jayanta Choudhury; Arun J. Sanyal
Journal:  Curr Treat Options Gastroenterol       Date:  2003-12

Review 10.  KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2018-07-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.